Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Emma Sangalang"'
Autor:
Tracy C. Kuo, Amy Chen, Ons Harrabi, Jonathan T. Sockolosky, Anli Zhang, Emma Sangalang, Laura V. Doyle, Steven E. Kauder, Danielle Fontaine, Sangeetha Bollini, Bora Han, Yang-Xin Fu, Janet Sim, Jaume Pons, Hong I. Wan
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-19 (2020)
Abstract Background Signal regulatory protein α (SIRPα) is a myeloid-lineage inhibitory receptor that restricts innate immunity through engagement of its cell surface ligand CD47. Blockade of the CD47–SIRPα interaction synergizes with tumor-spec
Externí odkaz:
https://doaj.org/article/aafee68f22694b6fb3c27f80eac48cb0
Autor:
Min Li, Ons Harrabi, Amy Chen, Emma Sangalang, Danielle Fontaine, Jaume Pons, Janet Sim, Tracy Kuo, Hong Wan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/ddedb858172e4602b6ba94434f44d43a
Autor:
Ons Harrabi, Amy Chen, Emma Sangalang, Laura Doyle, Danielle Fontaine, Bora Han, Curt Bradshaw, Jaume Pons, Janet Sim, Tracy Kuo, Hong Wan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/73729fd479f24e73bf97b54656bdd8b0
Autor:
Steven E Kauder, Tracy C Kuo, Ons Harrabi, Amy Chen, Emma Sangalang, Laura Doyle, Sony S Rocha, Sangeetha Bollini, Bora Han, Janet Sim, Jaume Pons, Hong I Wan
Publikováno v:
PLoS ONE, Vol 13, Iss 8, p e0201832 (2018)
CD47 is a widely expressed cell surface protein that functions as an immune checkpoint in cancer. When expressed by tumor cells, CD47 can bind SIRPα on myeloid cells, leading to suppression of tumor cell phagocytosis and other innate immune function
Externí odkaz:
https://doaj.org/article/3ebc34039c37468dbf22b9ca99bbcb93
Autor:
Amy Chen, Min Li, Maja Bonacorsi, Emma Sangalang, Danielle Fontaine, Ons Harrabi, Mingrui An, Tiffany Chou, Laura Doyle, Janet Sim, Bora Han, Hong Wan, Tracy Kuo, Maria Jose Costa, Pavel Strop
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::057faebb6fb75a55af2ff1773e5f0093
https://doi.org/10.1136/jitc-2022-sitc2022.1162
https://doi.org/10.1136/jitc-2022-sitc2022.1162
Autor:
Chen Amy Shaw-Ru, Anup Madan, Janet Sim, Ons Harrabi, Tracy C. Kuo, Hong Wan, Ardian S Wibowo, Shelley Izquierdo, Emma Sangalang, Darlene Pedersen, Josh Carter, Steven E. Kauder, Jonathan T. Sockolosky, Jaume Pons, Harriman William Don, Laura Doyle
Publikováno v:
mAbs
Targeting the CD47-signal-regulatory protein α (SIRPα) pathway represents a novel therapeutic approach to enhance anti-cancer immunity by promoting both innate and adaptive immune responses. Unlike CD47, which is expressed ubiquitously, SIRPα expr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66b6e62d7e10586ce646d15c3a63cebd
http://europepmc.org/articles/PMC6748616
http://europepmc.org/articles/PMC6748616
Autor:
Danielle Fontaine, Emma Sangalang, Amy Y. Chen, Laura V. Doyle, Ons Harrabi, Tracy C. Kuo, Bradshaw Curt W, Hong Wan, Jaume Pons, Janet Sim, Bora Han
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Toll-like receptor (TLR) pathways play a crucial role in mounting potent innate immune responses against invading pathogens, as well as the subsequent engagement of adaptive immunity. Innate immune activation via the TLR9 pathway has poten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df52fdb67dd48c56807f1bf94c7b774d
https://doaj.org/article/73729fd479f24e73bf97b54656bdd8b0
https://doaj.org/article/73729fd479f24e73bf97b54656bdd8b0
Autor:
Danielle Fontaine, Bora Han, Laura V. Doyle, Amy Y. Chen, Ons Harrabi, Hong I. Wan, Emma Sangalang, Janet Sim, Min Li, Jaume Pons, Tracy C. Kuo
Publikováno v:
Cancer Research. 81:1721-1721
Novel therapies capable of engaging both innate and adaptive immune responses may engender durable anti-tumor immunity. Activation of toll-like receptor 9 (TLR9) by unmethylated oligonucleotides promotes innate inflammatory responses and the inductio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18a284770f7c597de10a46d25480b91e
https://doi.org/10.1158/1538-7445.am2021-1721
https://doi.org/10.1158/1538-7445.am2021-1721
Autor:
Hong I. Wan, Emma Sangalang, Tracy C. Kuo, Ons Harrabi, Laura Doyle, Janet Sim, Jaume Pons, Bora Han, Amy Y. Chen, Sangeetha Bollini, Sony S. Rocha, Steven E. Kauder
Publikováno v:
PLoS ONE, Vol 13, Iss 8, p e0201832 (2018)
PLoS ONE
PLoS ONE
CD47 is a widely expressed cell surface protein that functions as an immune checkpoint in cancer. When expressed by tumor cells, CD47 can bind SIRPα on myeloid cells, leading to suppression of tumor cell phagocytosis and other innate immune function
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0084e4ed70449fa13ce8d6b32e9f2bad
http://europepmc.org/articles/PMC6104973?pdf=render
http://europepmc.org/articles/PMC6104973?pdf=render
Autor:
Sangeetha Bollini, Jaume Pons, Laura V. Doyle, Hong I. Wan, Ons Harrabi, Tracy C. Kuo, Steven E. Kauder, Emma Sangalang, Amy Y. Chen, Bora Han, Janet Sim
Publikováno v:
Cancer Research. 79:562-562
Targeting the CD47-SIRPα myeloid checkpoint pathway represents a novel therapeutic approach to enhance anti-cancer immunity. CD47 is a widely expressed cell surface protein that functions as a marker of self. Signal regulatory protein-α (SIRPα) is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf75345ae85a06dcfa261d130876ab91
https://doi.org/10.1158/1538-7445.am2019-562
https://doi.org/10.1158/1538-7445.am2019-562